Adaptive Biotechnologies Corp Surpasses Analyst Target Price of $17.14 with $17.36/Share

Adaptive Biotechnologies Corp (ADPT) has crossed above the average analyst 12-month target price of $17.14, reaching $17.36/share. There are 7 different analyst targets within the Zacks coverage universe contributing to the average, ranging from $11.00 to $20.00. The standard deviation is $3.236. Investors should assess the company and decide if $17.14 is a stop on the way to a higher target or if the valuation has gotten stretched.